Cargando…

Machine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug Discovery

BACKGROUND: Chagas disease is a neglected tropical disease (NTD) caused by the eukaryotic parasite Trypanosoma cruzi. The current clinical and preclinical pipeline for T. cruzi is extremely sparse and lacks drug target diversity. METHODOLOGY/PRINCIPAL FINDINGS: In the present study we developed a co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ekins, Sean, Lage de Siqueira-Neto, Jair, McCall, Laura-Isobel, Sarker, Malabika, Yadav, Maneesh, Ponder, Elizabeth L., Kallel, E. Adam, Kellar, Danielle, Chen, Steven, Arkin, Michelle, Bunin, Barry A., McKerrow, James H., Talcott, Carolyn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482694/ https://www.ncbi.nlm.nih.gov/pubmed/26114876 http://dx.doi.org/10.1371/journal.pntd.0003878

Ejemplares similares

Identification of Leucinostatins from Ophiocordyceps sp. as Antiparasitic Agents against Trypanosoma cruzi
por: Bernatchez, Jean A., et al.
Publicado: (2022)

Location, Location, Location: Five Facts about Tissue Tropism and Pathogenesis
por: McCall, Laura-Isobel, et al.
Publicado: (2016)

Long term follow-up of Trypanosoma cruzi infection and Chagas disease manifestations in mice treated with benznidazole or posaconazole
por: Calvet, Claudia Magalhães, et al.
Publicado: (2020)

Binding Mode and Potency of N-Indolyloxopyridinyl-4-aminopropanyl-Based Inhibitors Targeting Trypanosoma cruzi CYP51
por: Vieira, Debora F., et al.
Publicado: (2014)

High-Throughput Screening of the ReFRAME Library Identifies Potential Drug Repurposing Candidates for Trypanosoma cruzi
por: Bernatchez, Jean A., et al.
Publicado: (2020)

4-Aminopyridyl-Based CYP51 Inhibitors as Anti-Trypanosoma cruzi Drug Leads with Improved Pharmacokinetic Profile and in Vivo Potency
por: Calvet, Claudia M., et al.
Publicado: (2014)

Cysteine Protease Inhibitors Cure an Experimental Trypanosoma cruzi Infection
por: Engel, Juan C., et al.
Publicado: (1998)

Spatial metabolomics identifies localized chemical changes in heart tissue during chronic cardiac Chagas Disease
por: Dean, Danya A., et al.
Publicado: (2021)

The Trypanosoma cruzi Protease Cruzain Mediates Immune Evasion
por: Doyle, Patricia S., et al.
Publicado: (2011)

Dysregulation of Glycerophosphocholines in the Cutaneous Lesion Caused by Leishmania major in Experimental Murine Models
por: Parab, Adwaita R., et al.
Publicado: (2021)

Diverse Inhibitor Chemotypes Targeting Trypanosoma cruzi CYP51
por: Gunatilleke, Shamila S., et al.
Publicado: (2012)

Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole
por: Chen, Chiung-Kuang, et al.
Publicado: (2010)

In Vitro and In Vivo Studies of the Trypanocidal Properties of WRR-483 against Trypanosoma cruzi
por: Chen, Yen Ting, et al.
Publicado: (2010)

Targeting Ergosterol Biosynthesis in Leishmania donovani: Essentiality of Sterol 14alpha-demethylase
por: McCall, Laura-Isobel, et al.
Publicado: (2015)

4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection
por: Calvet, Claudia Magalhaes, et al.
Publicado: (2017)

Trypanosoma cruzi CYP51 Inhibitor Derived from a Mycobacterium tuberculosis Screen Hit
por: Chen, Chiung-Kuang, et al.
Publicado: (2009)

Genome-scale metabolic models highlight stage-specific differences in essential metabolic pathways in Trypanosoma cruzi
por: Shiratsubaki, Isabel S., et al.
Publicado: (2020)

Persistent biofluid small molecule alterations induced by Trypanosoma cruzi infection are not restored by antiparasitic treatment
por: Dean, Danya A., et al.
Publicado: (2023)

Experimental Chagas disease-induced perturbations of the fecal microbiome and metabolome
por: McCall, Laura-Isobel, et al.
Publicado: (2018)

An Image-Based Algorithm for Precise and Accurate High Throughput Assessment of Drug Activity against the Human Parasite Trypanosoma cruzi
por: Moon, Seunghyun, et al.
Publicado: (2014)

In vitro anti-Trypanosoma cruzi activity enhancement of curcumin by its monoketone tetramethoxy analog diveratralacetone
por: Souza, Julia M., et al.
Publicado: (2021)

Combining Metabolite-Based Pharmacophores with Bayesian Machine Learning Models for Mycobacterium tuberculosis Drug Discovery
por: Ekins, Sean, et al.
Publicado: (2015)

Molecular dissection of Chagas induced cardiomyopathy reveals central disease associated and druggable signaling pathways
por: Wozniak, Jacob M., et al.
Publicado: (2020)

A systematic review of the diagnostic aspects and use of Trypanosoma rangeli as an immunogen for Trypanosoma cruzi infection
por: Bayão, Taciana de Souza, et al.
Publicado: (2020)

Discovery of Triple Inhibitors of Both SARS-CoV-2 Proteases and Human Cathepsin L
por: Meewan, Ittipat, et al.
Publicado: (2022)

Cysteine proteases in protozoan parasites
por: Siqueira-Neto, Jair L., et al.
Publicado: (2018)

Current understanding of the Trypanosoma cruzi-cardiomyocyte interaction
por: Calvet, Claudia M., et al.
Publicado: (2012)

Profiling the Trypanosoma cruzi Phosphoproteome
por: Marchini, Fabricio K., et al.
Publicado: (2011)

Clathrin expression in Trypanosoma cruzi
por: Kalb, Ligia Cristina, et al.
Publicado: (2014)

Endothelial Transmigration by Trypanosoma cruzi
por: Coates, Bria M., et al.
Publicado: (2013)

The N-myristoylome of Trypanosoma cruzi
por: Roberts, Adam J., et al.
Publicado: (2016)

Lysophosphatidylcholine: A Novel Modulator of Trypanosoma cruzi Transmission
por: Silva-Neto, Mário A. C., et al.
Publicado: (2012)

World Class Parasites: Vol. X, Schistosomiasis
por: McKerrow, James
Publicado: (2006)

RNA Interference of Trypanosoma brucei Cathepsin B and L Affects Disease Progression in a Mouse Model
por: Abdulla, Maha-Hamadien, et al.
Publicado: (2008)

TB Mobile: a mobile app for anti-tuberculosis molecules with known targets
por: Ekins, Sean, et al.
Publicado: (2013)

New target prediction and visualization tools incorporating open source molecular fingerprints for TB Mobile 2.0
por: Clark, Alex M, et al.
Publicado: (2014)

Introduction to robotics /
por: McKerrow, Phillip, 1949-
Publicado: (1991)

Designing Drugs for Parasitic Diseases of the Developing World
por: McKerrow, James H
Publicado: (2005)

The diverse roles of cysteine proteases in parasites and their suitability as drug targets
por: McKerrow, James H.
Publicado: (2018)

Update on drug development targeting parasite cysteine proteases
por: McKerrow, James H.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_g2vg316u43kjo8huf6hp56cc0v